Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...
Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The convergence of advanced diagnostics and targeted therapeutics is reshaping cancer care, as September 2025...
Today announced that enrollment in the dose escalation cohorts of the Phase 1 trial, evaluating GTB-3650 ...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Ohio State University just unlocked why many cancer immunotherapies fail, identifying a protein...
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date...
Announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be ...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Major biotechnology companies are presenting multi-cancer detection data and breakthrough clinical results...